Core Insights - AC Immune SA reported a landmark collaboration with Takeda for the development of ACI-24.060, which includes an upfront payment of $100 million and potential total payments of approximately $2.1 billion [1][3] - The company is on track to report Phase 2 trial results for ACI-24.060 in Q2 2024, focusing on amyloid plaque reduction in Alzheimer's disease [2][4] - AC Immune has a strong financial position with CHF 104.8 million in cash at the end of Q1 2024, providing a runway for at least three years [6] Financial Highlights - The cash balance as of March 31, 2024, was CHF 104.8 million, an increase from CHF 103.1 million at the end of 2023, including CHF 47.8 million in cash and cash equivalents and CHF 57.0 million in short-term financial assets [6] - Research and development expenses for Q1 2024 were CHF 15.2 million, compared to CHF 13.9 million in the same period in 2023, primarily due to increased clinical expenses for ACI-24.060 [6] - The company reported a net loss of CHF 17.9 million for Q1 2024, slightly higher than the net loss of CHF 17.5 million in Q1 2023 [6][14] Pipeline Developments - ACI-24.060 is currently in the ABATE Phase 2 trial, with full enrollment in cohorts 1 and 2, and cohort 3 expected to complete enrollment by year-end [3] - The ACI-7104.056 VacSYn Phase 2 trial for Parkinson's disease is on track for interim safety and immunogenicity data in H2 2024 [5] - The ACI-35.030 anti-phospho-Tau active immunotherapy is being evaluated in a Phase 2b trial, with the first patient expected to be treated soon [5] Strategic Partnerships - The collaboration with Takeda aims to leverage both companies' expertise in neuroscience, enhancing AC Immune's position in the field of neurodegenerative diseases [2] - The agreement includes tiered royalties on worldwide net sales upon commercialization, further strengthening AC Immune's revenue potential [3]

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to h ...

, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

ANNUAL REPORT 2023 Contents | AC Immune Annual Report 2023 1 Contents 2 Operating and Financial Highlights Our goal is global leadership 3 Chair & CEO’s Statement ...

A downtrend has been apparent in AC Immune (ACIU) lately with too much selling pressure. The stock has declined 35.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spott ...

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will regain all glob ...

Wall Street had a disappointing start to 2024 as the nine-week winning streak snapped, erasing some of the strong gains seen at the end of 2023. Overstretched valuations and uncertainty around when the Fed will begin to cut rates have dampened investors’ optimism. The decline was broad-based, with small-cap stocks plunging the most.The Russell 2000 Index declined 3.7% in the initial week of 2024. The trend might reverse, given what is called the “January Effect," which refers to a seasonal increase in stock ...

Investors might want to bet on AC Immune (ACIU) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since ...

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to complete cohort 3 in January; 6-month and 12-month amyloid PET data expected in H1 & H2 2024, respectivelyReTain Phase 2b clinical trial of ACI-35.030 in preclinical AD being launched now by partner VacSYn Phase 2 PD trial of ACI-7104.056 completed enrollment of cohort 1 and commenced cohort 2; sa ...

Exhibit 99.1 Condensed Consolidated Balance Sheets (Unaudited) (In CHF thousands) As of September 30, December 31, Note 2023 2022 Assets Non-current assets Property, plant and equipment 5 3,627 4,259 Right-of-use assets 6 2,403 2,808 Intangible asset 9 50,416 50,416 Long-term financial assets 6 361 361 Total non-current assets 56,807 57,844 Current assets Prepaid expenses 10 5,534 4,708 Accrued income 3 312 408 Other current receivables 406 392 Short-term financial assets 11 48,000 91,000 Cash and cash equi ...